Techniques for In Vivo Glycobiology Disease Model Development

Techniques for In Vivo Glycobiology Disease Model Development

Unlocking Disease Insights: Advancing In Vivo Glycobiology with Cutting-Edge Techniques

The development of in vivo glycobiological disease models aims to gain insight into the pathogenesis and biological characteristics of diseases such as disorders of glucose metabolism. Through the application of advanced technologies such as gene editing, transgenic technology, and embryo implantation and culture, researchers can construct animal models that mimic human diseases, thereby enabling accurate simulation and control of the disease development process. CD BioGlyco provides one-stop Glycobiology Disease Model Development Services to clients based on different technologies. The technologies include but are not limited to the following.

Gene Editing

CD BioGlyco employs gene editing technology to accurately alter animal genomes for the creation of in vivo glycobiological models, aiding in the modeling of human diseases and the examination of specific gene functions and roles.

Transgenic Technology

We provide comprehensive transgenic-based in vivo glycobiology disease model development services to our clients. Our team is dedicated to providing reliable and high-quality support in the field of glycobiology.

Embryo Implantation and Cultivation

CD BioGlyco is dedicated to providing high-quality in vivo glycobiology disease model development service based on reliable embryo implantation and cultivation technology. Our emphasis is on precision, and attention to detail.

Selective Breeding

We perform artificial selection by selecting individuals with specific traits for reproduction to increase or decrease the frequency of these traits in the offspring for targeted construction of glycobiological disease models.

Gene Expression

Some diseases are associated with mutations in the activity of specific genes, CD BioGlyco offers gene expression-based in vivo glycobiology disease model development service to your research related to these glycobiology models.

Our glycobiology disease model development services are founded on various technologies, yet the process of these services remains similar.

We typically engage in thorough discussions with the client to gain a comprehensive understanding of the study objectives, disease selection, and anticipated outcomes. Subsequently, we carefully select suitable techniques and models and develop experimental protocols tailored to specific requirements. Following extensive preparatory work, we proceed with the construction of the glycobiological disease model. Finally, we conduct comprehensive data collection and analysis on the constructed disease model, encompassing phenotyping, biochemical index testing, etc., to ensure alignment with expected criteria.

CD BioGlyco possesses a state-of-the-art laboratory and utilizes advanced technologies for the development of in vivo glycobiology disease models. Our team of experts offers comprehensive services tailored to different needs, ensuring the highest quality results. Among them, our experts are skillful in operating knock-in, knockdown, and knock-out gene editing techniques in gene editing, striving to choose the most appropriate technology for your research. Similarly, we have first-class transgenic technologies, including but not limited to adenovirus-mediated transgenesis, transfection of embryonic stem cells, and embryo injection, and we aim to provide clients with the most comprehensive and professional service. In terms of embryo implantation and cultivation-based in vivo glycobiology disease model development, we utilize expertise in embryo transfection technology and embryo transfer techniques to provide reliable results. What's more, RT-qPCR, RNA sequencing, and microarray analysis are used in gene expression to confirm a completed service. Our experts have extensive experience in utilizing these techniques to study the regulation and function of genes in various biological processes. Additionally, they are proficient in data analysis and interpretation, allowing them to extract meaningful insights from complex gene expression datasets.

Technologies employed in the development of disease models for glycobiology research in living organisms. (CD BioGlyco)

Publication

Technology: Clustered regularly interspaced short palindromic repeats/CRISPR-associated protein 9 (CRISPR/Cas9)

Journal: Biomedicines

IF: 4.757

Published: 2023

Results: This article examines the advancements and future potential of gene editing in pluripotent stem cells. It emphasizes the significance of utilizing gene editing in human pluripotent stem cells, such as embryonic stem cells and induced pluripotent stem cells, for clinical cell therapy. First, since all mutations in pluripotent stem cells are passed on to their progeny, untargeted editing by editors is amplified. Pluripotent stem cells are highly susceptible to DNA damage, and the double-strand breaks caused by gene editing may result in ineffective editing and an increase in cell populations with compromised genome protection. To avoid these consequences, researchers prefer to use gene editing tools that do not rely on double-strand breaks, such as base-editing enzymes and primitive editing enzymes. In addition, Cas-associated nucleases, transposons, and recombinases are expanding the gene editing toolbox as the microbial world is better understood. The article also discusses current practical applications of gene editing in pluripotent stem cells using programmable nucleases, efforts by researchers to optimize these systems, and new tools that can potentially be used for differentiation modeling.

Fig.1 Gene editing is employed in pluripotent stem cells for both research and medical purposes.Fig.1 Gene editing in pluripotent stem cells used in research and medicine. (Zhang, et al., 2023)

Applications

  • Gene editing technology can be applied to the study of gene function and the construction of disease models.
  • The in vivo glycobiological disease models can be used to replicate disease progression, investigate the etiology and pathophysiology of diseases, and offer valuable insights into the mechanisms underlying disease development.
  • The in vivo glycobiological disease models can be used to study drug metabolism, efficacy, and pharmacokinetics in glycobiological disease models, providing an important reference for drug development.

Advantages

  • Our gene editing technology precisely modifies the target gene to achieve point mutation, gene deletion, insertion, or repair of a single base pair, improving the accuracy and controllability of the model.
  • The transgenic technology at CD BioGlyco allows researchers to precisely manipulate and regulate the expression levels of target genes to construct disease models that meet research needs, making models more controllable.
  • Our embryo implantation and culture techniques ensure the stability of disease models throughout the organism, facilitating long-term research and observation.

Through the establishment of cooperative relationships with pharmaceutical companies and academic institutions around the world, CD BioGlyco is constantly enhancing our knowledge to offer the most extensive technologies for developing in vivo glycobiology disease models. For further details, please don't hesitate to contact us.

Reference

  1. Zhang, Z.; et al. Progress and prospects of gene editing in pluripotent stem cells. Biomedicines. 2023, 11(8): 2168.
This service is for Research Use Only, not intended for any clinical use.

Christmas 2024

About Us

CD BioGlyco is a world-class biotechnology company with offices in many countries. Our products and services provide a viable option to what is otherwise available.

Contact Us

Copyright © CD BioGlyco. All rights reserved.
0